Open AccessRasburicase‐induced methemoglobinemia: case report, literature review, and proposed treatment algorithm
Author(s) -
Sherwood Garrett B.,
Paschal Rita D.,
Adamski Jill
Publication year - 2016
Publication title -
clinical case reports
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.21
H-Index - 9
ISSN - 2050-0904
DOI - 10.1002/ccr3.495
Subject(s) - rasburicase , methemoglobinemia , medicine , tumor lysis syndrome , anemia , hemolytic anemia , methylene blue , pediatrics , intensive care medicine , gastroenterology , chemotherapy , anesthesia , biochemistry , chemistry , photocatalysis , catalysis
Key Clinical Message Rasburicase for the treatment of tumor lysis syndrome has been associated with hemolytic anemia and methemoglobinemia, usually in patients with G6 PD deficiency. Risks and benefits should be considered prior to use of rasburicase in at‐risk patients. Methylene blue will worsen the hemolytic anemia in G6 PD deficiency and should be avoided.